<DOC>
	<DOC>NCT00483028</DOC>
	<brief_summary>To purpose of this study is to estimate the effect of donepezil on Neuropsychological Testing (NPT) and brain Proton Magnetic Resonance Spectroscopy.</brief_summary>
	<brief_title>A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<criteria>Healthy males or females ages 5590 inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and heart rate measurement, 12lead ECG and clinical laboratory tests) Body Mass Index (BMI) between 18 to 34 kg/m2, inclusive; and a total body weight Subjects with mild cognitive impairment (MCI) must have a reliable informant who has an average of 10 hours per week or more contact with the subject. Memory complaints and memory difficulties, which are verified by an informant Minimental status exam (MMSE) score of 2430 Subjects with known hypersensitivity to donepezil hydrochloride or to piperidine derivatives Insulinrequiring diabetes or uncontrolled diabetes mellitus Subjects with a current diagnosis of depression or other psychiatric illnesses</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>February 2008</verification_date>
</DOC>